Accessibility Menu
Tectonic Therapeutic logo

Tectonic Therapeutic(NASDAQ) TECX

Market Cap$584.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+82%
5 Year-67%
1 Year+41%
1 Month-13%
$30.99
+2.55%
+0.77Today
After hours$30.93-$0.06 (-0.19%)
Tectonic Therapeutic last closing stock price
MetricPriceDate
Last closeUSD 30.982026-08-07
Tectonic Therapeutic stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.52%USD 28.032026-07-31
1 month-12.68%USD 35.482026-07-08
3 month+6.83%USD 29.002026-05-08
Year to date+48.51%USD 20.862025-12-31
1 year+41.33%USD 21.922025-08-07
3 year+68.74%USD 18.362023-08-08
5 year-66.56%USD 92.642021-08-06
Since inception+82.13%USD 17.012024-06-21

Tectonic Therapeutic Financials at a Glance

Market Cap

$584.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$85.79M

EPS (TTM)

-$4.56

P/E Ratio

-6.79

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$30.99

Volume

271,645.383

Open

$30.79

Previous Close

$30.98

Daily Range

$30.45 - $31.84

52-Week Range

$14.39 - $39.53

Estimated Earnings Date

Aug 6, 2026

TECX News

Foolcom-Featured.png

Tectonic (TECX) Q2 R&D Soars 142%

Motley Fool Markets TeamAug 7, 2025

TECX: Motley Fool Moneyball Superscore

69

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tectonic Therapeutic

Tectonic Therapeutic develops proteins and antibodies for medical needs. Its GEODe platform targets G-protein coupled receptors. This technology aids in treating heart failure and other conditions.

Products and Services

GEODe Technology Platform: Develops biologics targeting G-protein coupled receptors (GPCRs).

TX000045 (TX45): Targets heart failure with preserved ejection fraction.

TX2100: Antagonist for hereditary hemorrhagic telangiectasia.

GPCR Modulator Bispecific: Targets fibrotic diseases.

RXFP1 Agonist: In phase 1 trials for heart failure.

Bi-functional GPCR Modulator: Addresses fibrosis-related conditions.

Growth and Expansion

Ongoing clinical trials for TX45 in heart failure conditions.

Planned Phase 1 trial for TX2100 in 2025/2026.

Expansion of GEODe platform capabilities in 2024.

What Makes Tectonic Special

Tectonic's GEODe platform offers unique biologic solutions for GPCR targets. This focus provides potential advantages in selectivity and dual target engagement.

Financial Highlights

No revenue or net sales figures disclosed as of 2024.

Market cap of $376.61M as of 2023.

Stock price range: $1.40 - $61.07 in 2023.

Beta of 1.38 indicates moderate market volatility.

Bottom Line

Tectonic Therapeutic is innovating in GPCR-targeted biologics. Its focus on unmet medical needs positions it uniquely in the biotechnology sector.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

60

CEO

Alise S. Reicin, MD

Website

www.tectonictx.com

Headquarters

Watertown, MA 02472, US

TECX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-35.26%

Return on Capital

-33.27%

Return on Assets

-36.19%

Earnings Yield

-14.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$584.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.87M

Volume

271.65K

Avg. Volume

194.23K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$94.93M

EBITDA

-$83.79M

Operating Cash Flow

-$90.55M

Capital Expenditure

-$325.00K

Free Cash Flow

-$90.88M

Cash & ST Invst.

$227.07M

Total Debt

$4.40M

Tectonic Therapeutic Performance Analysis

Tectonic Therapeutic annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tectonic Therapeutic sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Tectonic Therapeutic annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -29.05-12.9%
20232023-12-31USD -33.7616.2%
20242024-12-31USD -6.83-79.8%
20252025-12-31USD -4.05-40.7%
Tectonic Therapeutic sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-304.7%
Q42025-12-31-1.0%
Q12026-03-31-30.1%
Q22026-06-3011.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$584.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.74M

N/A

Employees

60

N/A

Net Income

-$22.29M

-11.5%

EBITDA

-$21.92M

-17.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$227.07M

-21.0%

Total Debt

$4.40M

+126.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.82M

+1415.6%

Short Term Debt

$1.58M

-10.1%

Return on Assets

-36.19%

N/A

Return on Invested Capital

-41.88%

N/A

Free Cash Flow

-$39.96M

-171.0%

Operating Cash Flow

-$39.86M

-170.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLNSilence Therapeutics plc
$11.95+1.96%
LRMRLarimar Therapeutics, Inc.
$4.16-0.95%
LYELLyell Immunopharma, Inc.
$14.71+3.52%
DBVTDBV Technologies S.A.
$13.48-1.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About TECX

What is the current price of Tectonic Therapeutic?

Tectonic Therapeutic is trading at $30.98 per share.

What is the 52-week range for Tectonic Therapeutic?

Over the past 52 weeks, Tectonic Therapeutic has traded between $14.39 and $39.53.

How much debt does Tectonic Therapeutic have?

As of the most recent reporting period, Tectonic Therapeutic reported total debt of $1.28M.

How much cash does Tectonic Therapeutic have on hand?

Tectonic Therapeutic reported $227.07M in cash and cash equivalents in its most recent financial results.

What is Tectonic Therapeutic’s dividend yield?

Tectonic Therapeutic does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services